Connor Clark & Lunn Investment Management Ltd. Purchases 56,028 Shares of ALX Oncology Holdings Inc. (NASDAQ:ALXO)

Connor Clark & Lunn Investment Management Ltd. lifted its position in ALX Oncology Holdings Inc. (NASDAQ:ALXO) by 207.4% during the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 83,042 shares of the company’s stock after purchasing an additional 56,028 shares during the quarter. Connor Clark & Lunn Investment Management Ltd. owned about 0.16% of ALX Oncology worth $151,000 at the end of the most recent quarter.

Several other institutional investors have also recently made changes to their positions in ALXO. CANADA LIFE ASSURANCE Co purchased a new position in ALX Oncology during the first quarter worth about $27,000. Zurcher Kantonalbank Zurich Cantonalbank boosted its position in shares of ALX Oncology by 394.8% during the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 6,517 shares of the company’s stock valued at $39,000 after acquiring an additional 5,200 shares during the last quarter. Rhumbline Advisers grew its holdings in shares of ALX Oncology by 10.8% during the second quarter. Rhumbline Advisers now owns 55,220 shares of the company’s stock worth $333,000 after purchasing an additional 5,360 shares in the last quarter. AQR Capital Management LLC increased its position in shares of ALX Oncology by 50.7% in the second quarter. AQR Capital Management LLC now owns 18,079 shares of the company’s stock worth $109,000 after purchasing an additional 6,080 shares during the last quarter. Finally, SG Americas Securities LLC raised its stake in ALX Oncology by 33.6% in the third quarter. SG Americas Securities LLC now owns 27,394 shares of the company’s stock valued at $50,000 after purchasing an additional 6,888 shares in the last quarter. Institutional investors own 97.97% of the company’s stock.

ALX Oncology Price Performance

Shares of NASDAQ:ALXO opened at $1.48 on Monday. The company’s fifty day moving average is $1.54 and its 200 day moving average is $4.37. The company has a quick ratio of 4.82, a current ratio of 4.82 and a debt-to-equity ratio of 0.07. ALX Oncology Holdings Inc. has a 52 week low of $1.19 and a 52 week high of $17.83. The stock has a market cap of $78.06 million, a PE ratio of -0.50 and a beta of 1.03.

Wall Street Analyst Weigh In

A number of research firms have commented on ALXO. Stifel Nicolaus reissued a “hold” rating and issued a $3.00 price target (down previously from $5.00) on shares of ALX Oncology in a research note on Friday, August 9th. Cantor Fitzgerald reissued an “overweight” rating on shares of ALX Oncology in a research note on Tuesday, November 12th. UBS Group dropped their price target on ALX Oncology from $25.00 to $4.00 and set a “buy” rating for the company in a research note on Friday, August 16th. Finally, HC Wainwright reiterated a “buy” rating and set a $25.00 price objective on shares of ALX Oncology in a research report on Tuesday, August 13th. Two research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $12.50.

ALX Oncology Profile

ALX Oncology Holdings Inc, a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company's lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic in development as a combination therapy with other anti-cancer agents, including ASPEN-06, under Phase 2 clinical study for treating Gastric/GEJ cancer; ASPEN-07, under Phase 1 clinical study for treating urothelial cancer; and ASPEN-03 and ASPEN-04, both under Phase 2 clinical study for treating head and neck squamous cell carcinoma.